CTI Launches Phase III Trial Of Pixantrone In Indolent NHL
This article was originally published in The Pink Sheet Daily
Executive Summary
Pixantrone provides improvement over standard care for patients with relapsed follicular disease, CEO Bianco tells “The Pink Sheet” DAILY.